文章：

靶向前列腺特异性膜抗原的放射性标记单克隆抗体在成像与治疗中的现状

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy

原文发布日期：13 September 2023

DOI: 10.3390/cancers15184537

类型: Article

开放获取: 是

英文摘要：

Prostate cancer (PCa) is one of the most prevalent cancer diagnoses among men in the United States and in several other developed countries. The prostate specific membrane antigen (PSMA) has been recognized as a promising molecular target in PCa, which has led to the development of specific radionuclide-based tracers for imaging and radiopharmaceuticals for PSMA targeted therapy. These compounds range from small molecule ligands to monoclonal antibodies (mAbs). Monoclonal antibodies play a crucial role in targeting cancer cell-specific antigens with a high degree of specificity while minimizing side effects to normal cells. The same mAb can often be labeled in different ways, such as with radionuclides suitable for imaging with Positron Emission Tomography (β+ positrons), Gamma Camera Scintigraphy (γ photons), or radiotherapy (β− electrons, α-emitters, or Auger electrons). Accordingly, the use of radionuclide-based PSMA-targeting compounds in molecular imaging and therapeutic applications has significantly grown in recent years. In this article, we will highlight the latest developments and prospects of radiolabeled mAbs that target PSMA for the detection and treatment of prostate cancer.

摘要翻译： 

前列腺癌（PCa）是美国及其他多个发达国家男性中最常见的癌症诊断之一。前列腺特异性膜抗原（PSMA）已被公认为前列腺癌中一个极具前景的分子靶点，这推动了基于特定放射性核素的示踪剂用于成像以及用于PSMA靶向治疗的放射性药物的开发。这些化合物从小分子配体到单克隆抗体（mAbs）不等。单克隆抗体在靶向癌细胞特异性抗原方面发挥着至关重要的作用，具有高度特异性，同时最大限度地减少对正常细胞的副作用。同一单克隆抗体通常可以通过不同方式进行标记，例如使用适合正电子发射断层扫描（β+正电子）、伽马相机闪烁扫描（γ光子）或放射治疗（β−电子、α发射体或俄歇电子）的放射性核素。因此，近年来基于放射性核素的PSMA靶向化合物在分子成像和治疗应用中的使用显著增长。在本文中，我们将重点介绍用于前列腺癌检测和治疗的靶向PSMA的放射性标记单克隆抗体的最新进展和前景。

原文链接：

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy